MyMD Pharmaceuticals Enrolls First Person in Phase 2 Medical Test of MYMD-1 as a Treatment for Delaying Aging as well as Increasing Healthy Life Expectancy

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Company”), a clinical phase pharmaceutical company devoted to expanding healthy and balanced life-span, today revealed that the first client has actually been enrolled in the Company’s Stage 2 scientific test of lead candidate MYMD-1, an oral immune regulator medicine, as a therapy for postponing aging and also broadening healthy and balanced lifespan.

The key endpoint for the Stage 2 double-blind, placebo-controlled medical trial is to attain a decrease in the distributing levels of (TNF-α), lump death factor receptor I (TNFRI) and also IL-6. TNF-α and IL-6 are the proteins in the body that trigger inflammation as well as assist trigger the procedure of aging. The additional procedures of the test will be the safety, tolerability, and also pharmacokinetics in this population of people.

” In a Stage 1 professional test of MYMD-1, we showed the medication’s statistically considerable efficacy in decreasing degrees of TNF-α, a principal in creating pathological aging, in the blood. The FDA has accepted TNF-α reduction as the main endpoint for our Stage 2 study, which our company believe positions us well for an effective Stage 2 result,” claimed Chris Chapman, M.D., President, Supervisor and Principal Medical Officer of MyMD. “The initiation of client registration in this study advancements our goal to slow down the aging procedure, prevent loss of muscle mass cells in aging, limit frailty, and expand healthy life-span.”

MyMD has actually mentioned that there are no FDA-approved drugs for treating aging problems and also prolonging healthy and balanced life-span human beings, a market anticipated to be a minimum of $600 billion by 20251 according to a significant investment financial institution. TNF-α blockers are one of the most prescribed medications by income, a worldwide market of about $40 billion each year,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would raise life span by one year deserves $38 trillion as well as by 10 years is worth $367 trillion.

In addition to aging, MYMD-1’s distinct action in controling the immune system as well as dealing with chronic inflammation is being created for the treatment of autoimmune illness, consisting of rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetes mellitus, and inflammatory digestive tract disease.

” We plan to start composing procedures for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The rising frequency of rheumatoid joint inflammation as well as other autoimmune and inflammatory diseases are driving demand for TNF preventions like MYMD-1, as well as our team believe our orally provided drug with very low poisoning would be turbulent to the $60 billion market for RA if accepted by the FDA for this indication.”

Rheumatoid joint inflammation impacts approximately 40 million individuals globally.4.

About MYMD-1.

Originally developed for autoimmune diseases, MYMD-1’s main function is to slow the aging process, avoid sarcopenia and frailty, and prolong healthy and balanced lifespan. Because it can cross the blood-brain obstacle and also get to the central nervous system (CNS), MYMD-1 is likewise positioned to be a feasible therapy for brain-related disorders. Its device of action and also effectiveness in diseases including several sclerosis (MS) and thyroiditis have been studied with partnerships with a number of scholastic establishments. MYMD-1 is also showing guarantee in pre-clinical studies as a possible treatment for message- COVID-19 issues and also as an anti-fibrotic and also anti-proliferation healing.

MYMD-1 has revealed effectiveness in pre-clinical studies in regulating the body immune system by performing as a discerning prevention of tumor death factor-alpha (TNF-α), a driver of chronic inflammation. Unlike various other treatments, MYMD-1 has actually been displayed in these pre-clinical research studies to precisely block TNF-α when it comes to be overactivated in autoimmune diseases as well as cytokine storms, yet not block it from doing its regular work of being a very first -responder to any kind of regular kind of moderate infection. MYMD-1’s ease of oral dosing is an additional differentiator compared to currently offered TNF-α blockers, every one of which need delivery by shot or mixture. No authorized TNF inhibitor has actually ever before been dosed by mouth. Furthermore, the medication is not immunosuppressive and has not been shown to trigger the severe negative effects usual with conventional therapies that treat inflammation.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional phase pharmaceutical business dedicated to prolonging healthy life expectancy, is focused on developing 2 novel healing systems that treat the causes of condition as opposed to only resolving the symptoms. MYMD-1 is a medicine platform based upon a scientific phase small molecule that controls the body immune system to regulate TNF-α, which drives persistent swelling, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, increase durability, and deal with autoimmune illness as well as COVID-19- connected anxiety. The Company’s 2nd drug system, Supera-CBD, is being established to treat chronic discomfort, addiction and also epilepsy. Supera-CBD is an unique artificial derivative of cannabidiol (CBD) and is being developed to resolve and surpass the swiftly expanding CBD market, which includes both FDA approved medications and also CBD items not currently regulated as medicines. For more details, visit www.mymd.com.